Characterisation of the temporal sequence of osteoblast gene expression during estrogen-induced osteogenesis in female mice.
Osteoblast differentiation under in vitro conditions is associated with increased expression of non-collagenous bone proteins including osteocalcin, osteopontin, and osteonectin, the exact function of which remain poorly understood. To determine whether these proteins play an important role in the formation of mineralised bone matrix by osteoblasts in vivo, we analysed the time-course of their expression during estrogen-induced osteogenesis in female mice, and compared this with the formation of new cancellous bone. Female mice were sacrificed prior to or following treatment with 17beta-estradiol for up to 32 days (500 microg/animal/week). Total RNA was extracted from femurs, and changes in expression of genes for a range of osteoblast-derived proteins assessed by Northern blot analysis. In parallel experiments, the time course of cancellous bone formation was determined by measuring bone mineral density (BMD) of the distal femur. Estrogen led to a rapid increase in BMD, which reached significance by Day 16. This was preceded by three-fold increases in expression of alkaline phosphatase (ALP) and type I collagen (COL I) at Days 8 and 12 respectively. In contrast, osteocalcin, osteopontin, and osteonectin expression showed no change during this initial period, although modest increases were observed at later times (i.e., Days 20 and 24). Our results suggest that osteocalcin, osteopontin, and osteonectin are not involved in the initial phase of the osteogenic response to estrogen, suggesting that these non-collagenous bone proteins do not play a direct role in the formation of mineralised bone matrix by osteoblasts in vivo.
Plant
A
A
Rheumatology Unit, University of Bristol, Division of Medicine, Bristol, United Kingdom.
Tobias
J H
JH
D000469:Alkaline Phosphatase / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D003094:Collagen / Q000096:biosynthesis / Q000235:genetics; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005269:Femur / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D051379:Mice; D008808:Mice, Inbred CBA; D010006:Osteoblasts / Q000378:metabolism* / Q000502:physiology*; D015675:Osteocalcin / Q000096:biosynthesis / Q000235:genetics; D010012:Osteogenesis / Q000187:drug effects; D015676:Osteonectin / Q000096:biosynthesis / Q000235:genetics; D053495:Osteopontin; D012333:RNA, Messenger / Q000096:biosynthesis; D012795:Sialoglycoproteins / Q000096:biosynthesis / Q000235:genetics; D015533:Transcriptional Activation
D015676:Osteonectin; D012333:RNA, Messenger; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D015675:Osteocalcin; D053495:Osteopontin; D004958:Estradiol; D003094:Collagen; D000469:Alkaline Phosphatase